Pharmacokinetics and bioavailability of flumequine in blunt snout bream (Megalobrama amblycephala) after intravascular and oral administrations.
In this study, the pharmacokinetic profile of flumequine (FMQ) was investigated in blunt snout bream (Megalobrama amblycephala) after intravascular (3 mg/kg body weight (b.w.)) and oral (50 mg/kg b.w.) administrations. The plasma samples were determinedby ultra-performance liquid chromatography (UPLC) with fluorescence detection. After intravascular administration, plasma concentration-time curves were best described by a two-compartment open model. The distribution half-life (t1/2α ), elimination half-life (t1/2β ), and area under the concentration-time curve (AUC) of blunt snout bream were 0.6 h, 25.0 h, and 10612.7 h·μg/L, respectively. After oral administration, a two-compartment open model with first-order absorption was also best fit the data of plasma. The t1/2α , t1/2β , peak concentration (Cmax ), time-to-peak concentration (Tmax ), and AUC of blunt snout bream were estimated to be 2.5 h, 19.7 h, 3946.5 μg/L, 1.4 h, and 56618.1 h. μg/L, respectively. The oral bioavailability (F) was 32.0%. The pharmacokinetics of FMQ in blunt snout bream displayed low bioavailability, rapid absorption, and rapid elimination.